2.23
Schlusskurs vom Vortag:
$2.26
Offen:
$2.27
24-Stunden-Volumen:
146.02K
Relative Volume:
0.37
Marktkapitalisierung:
$234.62M
Einnahmen:
$7.05M
Nettoeinkommen (Verlust:
$-30.43M
KGV:
-5.887
EPS:
-0.3788
Netto-Cashflow:
$21.84M
1W Leistung:
-1.33%
1M Leistung:
+3.24%
6M Leistung:
+3.24%
1J Leistung:
+18.30%
Proqr Therapeutics N V Stock (PRQR) Company Profile
Firmenname
Proqr Therapeutics N V
Sektor
Branche
Telefon
-
Adresse
-
Vergleichen Sie PRQR mit anderen Aktien
Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
---|---|---|---|---|---|---|
![]()
PRQR
Proqr Therapeutics N V
|
2.23 | 238.08M | 7.05M | -30.43M | 21.84M | -0.3788 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
469.65 | 121.28B | 11.10B | -988.90M | -1.26B | -3.92 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
563.10 | 60.96B | 14.09B | 4.50B | 2.96B | 39.28 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
328.81 | 42.77B | 2.35B | -269.70M | -75.39M | -2.09 |
![]()
ARGX
Argen X Se Adr
|
591.99 | 36.21B | 2.58B | 1.06B | -1.28B | 16.33 |
![]()
ONC
Beone Medicines Ltd Adr
|
291.47 | 32.08B | 3.81B | -644.79M | -669.77M | -6.24 |
Proqr Therapeutics N V Stock (PRQR) Upgrades & Downgrades
Datum | Aktion | Analytiker | Ratingänderung |
---|---|---|---|
2025-04-29 | Fortgesetzt | Cantor Fitzgerald | Overweight |
2025-04-29 | Eingeleitet | Evercore ISI | Outperform |
2025-03-10 | Hochstufung | Citigroup | Neutral → Buy |
2025-01-10 | Eingeleitet | Oppenheimer | Outperform |
2024-10-29 | Hochstufung | Raymond James | Outperform → Strong Buy |
2023-11-08 | Hochstufung | Chardan Capital Markets | Neutral → Buy |
2023-03-30 | Hochstufung | JMP Securities | Mkt Perform → Mkt Outperform |
2022-12-22 | Hochstufung | Cantor Fitzgerald | Neutral → Overweight |
2022-02-14 | Herabstufung | Citigroup | Buy → Neutral |
2022-02-11 | Herabstufung | Raymond James | Strong Buy → Mkt Perform |
2022-02-11 | Herabstufung | Stifel | Buy → Hold |
2022-02-01 | Eingeleitet | Raymond James | Strong Buy |
2021-05-03 | Eingeleitet | Stifel | Buy |
2021-03-25 | Bestätigt | Citigroup | Buy |
2020-11-03 | Fortgesetzt | Cantor Fitzgerald | Overweight |
2019-03-12 | Bestätigt | Chardan Capital Markets | Buy |
2018-12-19 | Eingeleitet | RBC Capital Mkts | Outperform |
2018-11-15 | Eingeleitet | Citigroup | Buy |
2018-09-19 | Eingeleitet | Evercore ISI | Outperform |
2017-09-26 | Bestätigt | JMP Securities | Mkt Outperform |
2016-06-20 | Eingeleitet | Chardan Capital Markets | Neutral |
2014-10-15 | Eingeleitet | Deutsche Bank | Buy |
2014-10-13 | Eingeleitet | H.C. Wainwright | Buy |
Alle ansehen
Proqr Therapeutics N V Aktie (PRQR) Neueste Nachrichten
Brokerages Set ProQR Therapeutics N.V. (NASDAQ:PRQR) Target Price at $8.00 - Defense World
What institutional investors are buying ProQR Therapeutics N.V. stockFree Consultation - jammulinksnews.com
Does ProQR Therapeutics N.V. stock perform well during market downturnsCapitalize on emerging investment opportunities - jammulinksnews.com
ProQR Therapeutics N.V. (NASDAQ:PRQR) Given Average Recommendation of "Buy" by Analysts - MarketBeat
When is ProQR Therapeutics N.V. stock expected to show significant growthUnbelievable profit margins - jammulinksnews.com
Is ProQR Therapeutics N.V. stock a growth or value playFree Real-Time Stock Data - Newser
Is ProQR Therapeutics N.V. stock overvalued or undervaluedInvest smarter with daily market updates - jammulinksnews.com
Buy Signal for ProQR Therapeutics N.V. Stock Key Technical Indicators to WatchFree Investment Community - Newser
How ProQR Therapeutics N.V. stock performs during market volatilityFree Stock Market Strategy Classes - Newser
Why ProQR Therapeutics N.V. stock attracts strong analyst attentionBest Stocks for Capital Safety - Newser
ProQR Therapeutics N.V. Company Revenue and Profit Trends: A Deep DiveFree Stock Market Beginners Guide - Newser
Is ProQR Therapeutics N.V. a good long term investmentFree Popular Stock Recommendations - PrintWeekIndia
ProQR Therapeutics N.V. Stock Analysis and ForecastMarket-leading growth rates - Autocar Professional
Will ProQR Therapeutics N.V. stock benefit from interest rate changesAccelerated financial growth - jammulinksnews.com
What drives ProQR Therapeutics N.V. stock priceStrong return on assets - Autocar Professional
What analysts say about ProQR Therapeutics N.V. stockUnprecedented profit potential - Autocar Professional
Owning 32% shares,institutional owners seem interested in ProQR Therapeutics N.V. (NASDAQ:PRQR), - Yahoo Finance
ProQR stock rating reiterated by Cantor Fitzgerald ahead of key 2H25 data - Investing.com Nigeria
What makes ProQR Therapeutics N.V. stock price move sharplyFree Wealth-Building Investment Strategies - Newser
ProQR Therapeutics N.V.'s (NASDAQ:PRQR) high institutional ownership speaks for itself as stock continues to impress, up 16% over last week - simplywall.st
ProQR Therapeutics N.V. (NASDAQ:PRQR) Shares Acquired by OneDigital Investment Advisors LLC - Defense World
ProQR Therapeutics (NASDAQ:PRQR) Stock Price Crosses Above Fifty Day Moving AverageWhat's Next? - MarketBeat
Vontobel Holding Ltd. Invests $48,000 in ProQR Therapeutics N.V. (NASDAQ:PRQR) - Defense World
ProQR Therapeutics’ SWOT analysis: RNA editing pioneer’s stock faces clinical hurdles - Investing.com Australia
ProQR Therapeutics’ SWOT analysis: RNA editing pioneer’s stock faces clinical hurdles By Investing.com - Investing.com South Africa
ProQR Therapeutics N.V. (NASDAQ:PRQR) Given Average Rating of "Buy" by Analysts - MarketBeat
ProQR Therapeutics' (PRQR) "Market Outperform" Rating Reaffirmed at JMP Securities - MarketBeat
ProQR Therapeutics (NASDAQ:PRQR) Given Market Outperform Rating at JMP Securities - Defense World
PRQR: Cantor Fitzgerald Reiterates Overweight Rating | PRQR Stoc - GuruFocus
ProQR stock advances as Cantor Fitzgerald reaffirms $8 price target By Investing.com - Investing.com Canada
ProQR stock advances as Cantor Fitzgerald reaffirms $8 price target - Investing.com
Finanzdaten der Proqr Therapeutics N V-Aktie (PRQR)
Umsatz
Nettogewinn
Free Cashflow
ENV
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):